Daniel Patrick O’day Sells 15,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the completion of the transaction, the chief executive officer directly owned 607,133 shares in the company, valued at $76,674,826.57. This trade represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Monday, June 1st, Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00.
• On Tuesday, April 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00.

Gilead Sciences Price Performance

GILD opened at $131.27 on Friday. Gilead Sciences, Inc. has a twelve month low of $107.75 and a twelve month high of $157.29. The company’s 50-day moving average price is $129.44 and its two-hundred day moving average price is $134.53. The stock has a market cap of $162.98 billion, a price-to-earnings ratio of 17.88 and a beta of 0.32. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the previous year, the firm posted $1.81 EPS. Gilead Sciences’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were paid a $0.82 dividend. The ex-dividend date was Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is presently 44.69%.

Analysts Set New Price Targets

Several research firms have recently weighed in on GILD. Daiwa Securities Group cut their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. Morgan Stanley lowered their price objective on Gilead Sciences from $175.00 to $168.00 in a research note on Friday, May 8th. Royal Bank Of Canada reaffirmed a “sector perform” rating on shares of Gilead Sciences in a report on Monday, June 8th. Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price for the company in a research report on Wednesday, May 20th. Finally, Citigroup lifted their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Twenty-five analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $158.41.

Institutional Trading of Gilead Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares in the last quarter. State Street Corp increased its holdings in shares of Gilead Sciences by 1.9% in the fourth quarter. State Street Corp now owns 60,240,518 shares of the biopharmaceutical company’s stock worth $7,393,921,000 after purchasing an additional 1,151,213 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Gilead Sciences by 4.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 27,698,660 shares of the biopharmaceutical company’s stock worth $3,399,734,000 after buying an additional 1,195,269 shares in the last quarter. Bank of America Corp DE raised its position in shares of Gilead Sciences by 15.2% in the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after buying an additional 3,046,688 shares in the last quarter. Finally, Norges Bank bought a new stake in Gilead Sciences during the fourth quarter valued at $2,617,152,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.